Journal of General Virology · 2004 · 65 citations · 25 references
Life SciencesImmunologyInfectious DiseasesMolecular VirologyVaccinologyVirologyAntiviral ImmunityVector-based VaccinesViral InfectionsViral PathogenesisViral VaccinesViral Vector VaccinesAdenoviral Vaccine VectorsAdenoviral VectorsAdenovirus VaccinesAdenovirus VectorsCoronavirus VaccinesT-cell Immune ResponsesT-cell Mediated ImmunityT-cell Mediated Responses
Severe acute respiratory syndrome coronavirus (SARS-CoV) has been identified as the aetiological agent of SARS. Thus, vaccination against SARS-CoV may represent an effective approach towards controlling SARS. The nucleocapsid (N) protein is thought to play a role in induction of cell-mediated immunity to SARS-CoV and thus it is important to characterize this protein. In the present study, an E1/partially E3-deleted, replication-defective human adenovirus 5 (Ad5) vector (Ad5-N-V) expressing the SARS-CoV N protein was constructed. The N protein, expressed in vitro by Ad5-N-V, was of the expected molecular mass of 50 kDa and was phosphorylated. Vaccination of C57BL/6 mice with Ad5-N-V generated potent SARS-CoV-specific humoral and T cell-mediated immune responses. These results show that Ad5-N-V may potentially be used as a SARS-CoV vaccine.
25
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Paul A. Rota, M. Steven Oberste, Stephan S. Monroe et al. · Science · 2003 · 2.6K citations · Full text
The Genome Sequence of the SARS-Associated Coronavirus
Marco A. Marra, Steven J.M. Jones, Caroline R. Astell et al. · Science · 2003 · 2.1K citations
John W. Shiver, Tong‐Ming Fu, Ling Chen et al. · Nature · 2002 · 1.2K citations · Full text
Development of a preventive vaccine for Ebola virus infection in primates
Nancy J. Sullivan, Anthony Sanchez, Pierre E. Rollin et al. · Nature · 2000 · 661 citations